endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF. 

You can contact us, or follow us on Twitter.

Watch the two-minute animation

The endTB-Q clinical trial results are in!

Lorenzo Guglielmetti at the Union World Conference

The endTB consortium is pleased to share the endTB-Q clinical trial results! The first Phase 3 randomized controlled trial to exclusively enroll people with pre-extensively drug-resistant tuberculosis (pre-XDR-TB), a very hard-to-treat form of tuberculosis (TB)...

FIND OUT ABOUT THE RESULTS HERE

endTB participant

Major advance in the fight against MDR-TB: four new short and effective treatments approved by the WHO

Paris, 19 August 2024 - In a rapid communication, the World Health Organization (WHO) recommended 3 new regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB), which were studied in the endTB clinical trial. This is a breakthrough in the fight against MDR-TB worldwide.

Read more here

PIH MSF MSF Unitaid: Save Lives Faster Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo